High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Abstract EN

Background.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide.

The JAK/STAT signaling pathway is involved in pancreatic cancer tumorigenesis.

However, the prognostic value of JAK2 expression in resectable PDAC is unclear.

Method.

In this study, we performed a clinicopathological analysis of 62 resectable PDAC cases with a primary focus on survival.

JAK2 expression was examined by immunohistochemistry.

The relationship between JAK2 expression and clinicopathological features and prognosis was analyzed.

Results.

Survival curve analyses revealed that high levels of JAK2 expression predict a poor prognosis in resectable PDAC patients.

Multivariate analysis confirmed that JAK2 expression can predict the prognosis of PDAC.

Conclusions.

Assessment of JAK2 protein expression may be a promising method to predict prognosis in patients with resectable PDAC.